PT  - JOURNAL ARTICLE
AU  - Meller, Megan E.
AU  - Pfaff, Bridget L.
AU  - Borgert, Andrew J.
AU  - Richmond, Craig S.
AU  - Athas, Deena M.
AU  - Kenny, Paraic A.
AU  - Sabin, Arick P.
TI  - Optimized infection control practices augment the robust protective effect of vaccination for ESRD patients during a hemodialysis facility SARS-CoV-2 outbreak
AID  - 10.1101/2022.03.18.22272356
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.18.22272356
4099  - http://medrxiv.org/content/early/2022/03/25/2022.03.18.22272356.short
4100  - http://medrxiv.org/content/early/2022/03/25/2022.03.18.22272356.full
AB  - Background While dialysis patients are at greater risk of serious SARS-CoV-2 complications, stringent infection prevention measures can help mitigate the risk of infection and transmission within dialysis facilities. We describe an outbreak of 14 cases diagnosed in a 13-day period in the second quarter of 2021 in a hospital-based ESRD facility, and our coordinated use of epidemiology, viral genome sequencing, and infection control practices to quickly end the cycle of transmission.Methods Symptomatic patients and staff members were diagnosed via RT-PCR tests. Facility-wide screening was conducted using rapid SARS-CoV-2 antigen tests. SARS-CoV-2 genome sequences were obtained from residual diagnostic PCR specimens.Results Of the 106 patients who received dialysis in the facility, 10 were diagnosed with SARS-CoV-2 infection, as was one patient support person. Of three positive staff members, two were unvaccinated and had provided care for six and four of the affected patients, respectively. Sequencing demonstrated that all the cases in the cluster shared an identical B.1.1.7./Alpha substrain. Attack rates were greatest among unvaccinated patients and staff. Vaccine effectiveness was 88% among patients.Conclusions Prompt recognition of an infection cluster and rapid intervention efforts successfully ended the outbreak. Alongside consistent adherence to core infection prevention measures, vaccination was highly effective in reducing disease incidence and morbidity in this vulnerable population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by an Emergent Ventures Fast Grant [grant number 2243] to PK and by the Gundersen Medical Foundation. PK holds the Dr. Jon & Betty Kabara Endowed Chair in Precision Oncology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Specimens were analyzed under a protocol approved by the Gundersen Health System Institutional Review Board (#2-20-03-008; PI: Kenny) to perform next-generation sequencing on remnant specimens after completion of diagnostic testing. Testing of identified specimens was explicitly permitted, as was chart review to correlate viral genome data with data abstracted from clinical notes on diagnosis, symptoms, relevant co-morbidities, clinical course and resolution of the SARS-CoV-2 infection in these patients. Scientific publication of deidentified data was also permitted. Submission of this manuscript was also approved by the Legal Department of Gundersen Health System. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data for viral genomes are deposited in GISAID with the strain names shown in Figure 2 and with the following EPI_ISL accession numbers: 2249220, 2249226, 2376250, 2376251, 2376252, 2500993, 2500994, 2500995, 2500996, 2500997, 2500998 and 2500999. https://www.gisaid.org/